1 reports of this reaction
16.7% of all OCTINOXATE, TITANIUM DIOXIDE reports
#3 most reported adverse reaction
PRODUCT FORMULATION ISSUE is the #3 most commonly reported adverse reaction for OCTINOXATE, TITANIUM DIOXIDE, manufactured by NARS Cosmetics. There are 1 FDA adverse event reports linking OCTINOXATE, TITANIUM DIOXIDE to PRODUCT FORMULATION ISSUE. This represents approximately 16.7% of all 6 adverse event reports for this drug.
Patients taking OCTINOXATE, TITANIUM DIOXIDE who experience product formulation issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT FORMULATION ISSUE is a frequently reported adverse event for OCTINOXATE, TITANIUM DIOXIDE, accounting for a significant proportion of all reports.
In addition to product formulation issue, the following adverse reactions have been reported for OCTINOXATE, TITANIUM DIOXIDE:
The following drugs have also been linked to product formulation issue in FDA adverse event reports:
PRODUCT FORMULATION ISSUE has been reported as an adverse event in 1 FDA reports for OCTINOXATE, TITANIUM DIOXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT FORMULATION ISSUE accounts for approximately 16.7% of all adverse event reports for OCTINOXATE, TITANIUM DIOXIDE, making it one of the most commonly reported side effect.
If you experience product formulation issue while taking OCTINOXATE, TITANIUM DIOXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.